Equities Analysts Issue Forecasts for SLN FY2030 Earnings

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) – Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Silence Therapeutics in a note issued to investors on Friday, March 13th. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($1.95) per share for the year. HC Wainwright has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.77) per share.

SLN has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Thursday, January 22nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Silence Therapeutics in a research note on Thursday, March 5th. Finally, William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $34.50.

Silence Therapeutics Stock Up 6.5%

Shares of Silence Therapeutics stock opened at $7.35 on Monday. The firm has a market cap of $347.14 million, a PE ratio of -3.93 and a beta of 1.32. Silence Therapeutics has a 52 week low of $1.97 and a 52 week high of $7.91. The business’s fifty day simple moving average is $5.40 and its 200-day simple moving average is $5.83.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.07. Silence Therapeutics had a negative return on equity of 101.71% and a negative net margin of 15,851.88%.The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $2.19 million.

Institutional Trading of Silence Therapeutics

Large investors have recently modified their holdings of the stock. Evelyn Partners Investment Management Services Ltd raised its stake in shares of Silence Therapeutics by 481.3% in the second quarter. Evelyn Partners Investment Management Services Ltd now owns 14,334 shares of the company’s stock valued at $77,000 after acquiring an additional 11,868 shares in the last quarter. Jane Street Group LLC acquired a new position in Silence Therapeutics during the 4th quarter worth $177,000. ADAR1 Capital Management LLC grew its stake in Silence Therapeutics by 26.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock worth $144,000 after purchasing an additional 5,000 shares in the last quarter. Massar Capital Management LP purchased a new stake in Silence Therapeutics during the 2nd quarter worth about $115,000. Finally, Citadel Advisors LLC purchased a new stake in Silence Therapeutics during the 3rd quarter worth about $112,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.